RNAi agents for inhibiting the expression of the alpha-1 antitrypsin (AAT) gene, compositions including AAT RNAi agents, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more AAT RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the AAT RNAi agent(s) to liver cells in vivo inhibits AAT gene expression and treats diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, and fulminant hepatic failure.

In an embodiment, present invention relates to a method of generating, ex vivo production of soluble Lox-1 (sLox-1), comprising: introducing a sample containing blood into a device; adding a coagulation enhancing material in the sample to form a cultured blood clot; incubating the cultured blood clot in the device at a temperature greater than 25? C. and less than 45? C. for at least 2 hours to allow production of Lox-1 from neutrophils of blood and to shed the sLox-1 outside the cultured blood clot; and collecting sLox-1 shedded in the device, wherein the method is configured to shed sLox-1 more than fresh blood.

A method of treating a patient infected with SARS-COV-2 virus includes phenotyping a sample obtained from the patient; and administering alpha-1-antitrypsin to the patient only if an alpha-1-antitrypsin C phenotype is detected in the sample. A kit configured to detect a SARS-COV-2 infection and an alpha-1-antitrypsin C phenotype includes a first sample collection container for holding a sample to be tested for a SARS-COV-2 infection; and a second sample collection container for holding a sample to be tested for alpha-1-antitrypsin phenotype C.

Described is a method of detecting a protein fragment in a urine sample and a serum sample. The protein fragment is a urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, or serum osteopontin fragment. The urine sample and the serum sample are obtained from the same individual.

Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.

RNAi agents for inhibiting the expression of the alpha-1 antitrypsin (AAT) gene, compositions including AAT RNAi agents, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more AAT RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the AAT RNAi agent(s) to liver cells in vivo inhibits AAT gene expression and treats diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, and fulminant hepatic failure.

A membrane-based assay device, methods and kits for determining the presence or quantity of an analyte in a test sample are provided. The immunochromatographic device comprises a membrane having a capture antibody bound thereto at a test zone, wherein the capture antibody is capable of binding with an analyte, in particular a Z-AAT protein present in a sample from a PiZ gene carrier.

The present disclosure relates to the field of molecular biology and more specifically to methods for detecting anti-carbamylated protein (anti-CarP) antibodies in the serum of rheumatoid arthritis (RA) patients.

The present invention provides compounds and methods for the treatment of an individual having or at risk of having a condition associated with alpha-1-antitrypsin by using a pharmacological chaperone. In particular, such methods are useful for the treatment and/or prevention of lung disorders associated with alpha-1-antitrypsin deficiency as well as liver disorders associated with an excess of alpha-1-antitrypsin. Suitable pharmacological chaperones include peptides and low-molecular weight compounds. The present invention also provides an assay for determining whether a test compound modulates alpha-1-antitrypsin activity.

Disclosed is a method for diagnosing a cancer health state, or a change in cancer health state in a patient, or for diagnosing a risk of the change or presence of a cancer in a patient, comprising determining, in a plasma sample from said patient, one or more biomarker values that correspond to alpha-1 antitrypsin (A1AT)-containing complex structures, and assigning the patient as having or not having cancer, or having or not having a change in cancer health state, or having or not having a risk of cancer based on said biomarker values, wherein said cancer is selected from the group consisting of hepatocellular carcinoma (HCC), ovarian cancer (OC), and breast cancer (BC).